Cysteine-rich 61 (Cyr61): a biomarker reflecting disease activity in rheumatoid arthritis

Arthritis Research & Therapy

Guangtao Li¹  Xinlei Yang¹  Xiaoying Sun¹  Yanjie Hao¹  Juan Zhao¹  Yong Fan¹  Yanrong Huang¹  Zhuoli Zhang¹  Wenhui Xie¹ 

[1] 0000 0004 1764 1621, grid.411472.5, Department of Rheumatology and Clinical Immunology, Peking University First Hospital, No.8, Xishiku Street, West District, 100034, Beijing, China;

关键词: Rheumatoid arthritis;    Cysteine-rich protein 61;    Biomarker;    Disease activity;    Treatment response;   

DOI  :  10.1186/s13075-019-1906-y

来源: publisher

【 摘 要 】

BackgroundNumerous preclinical studies have revealed a critical role of cysteine-rich 61 (Cyr61) in the pathogenesis of rheumatoid arthritis (RA). But there is little literature discussing the clinical value of circulation Cyr61 in RA patients. The aim of our study is to investigate the serum Cyr61 level and its association with disease activity in RA patients.MethodsA training cohort was derived from consecutive RA patients who visited our clinic from Jun 2014 to Nov 2018. Serum samples were obtained at the enrollment time. To further confirm discovery, an independent validation cohort was set up based on a registered clinical trial. Paired serum samples of active RA patients were respectively collected at baseline and 12 weeks after uniformed treatment. Serum Cyr61 concentration was detected by enzyme-linked immunosorbent assay. The comparison of Cyr61 between RA patients and controls, the correlation between Cyr61 levels with disease activity, and the change of Cyr61 after treatment were analyzed by appropriate statistical analyses.ResultsA total of 177 definite RA patients and 50 age- and gender-matched healthy controls were enrolled in the training cohort. Significantly elevated serum Cyr61 concentration was found in RA patients, demonstrating excellent diagnostic ability to discriminate RA from healthy controls (area under the curve (AUC) = 0.98, P <  0.001). In addition, the Cyr61 level in active RA patients was significantly lower than that in patients in remission/low disease activity, and it was inversely correlated with composite disease activity scores and almost all of the components in statistic. Further study in the validation cohort (n = 77) showed a significant increase of the Cyr61 level at 12 weeks in ACR responders (ACR20/50/70), while no significant change of the Cyr61 level from baseline was observed in non-responders.ConclusionsSerum Cyr61 levels were remarkably increased in RA patients compared with those in healthy controls. The Cyr61 concentration was inversely correlated with RA disease activity and upregulated in those therapeutic responders.Trial registrationCombination Therapy Prevents the Relapse of RA, NCT02320630. Registered 19 December 2014,

【 授权许可】

CC BY